AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Acquisition 17 Sep - Board approved USD 2 million investment in Mom’s Belief US Inc on 17 September 2026.
Source: Bse
Rays of Belief Limited (MOMSBELIEF)
Micro CapHealthcare stocks · Micro cap · NSE
Rays of Belief Limited operates in Hospital, within the Healthcare sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityVerify one data layerQuote updated 04 Nov, 03:31 pm ISTDetails
Quote04 Nov, 03:31 pm IST
Base fundamentals02 Nov 2026 · screener
Latest result29 Sept, 01:53 am IST
Score05 Nov, 04:30 am IST · v4.3-runtime-valuation
Tags20 Sept 2026
Coverage9/14 · 64%
Valuation2026-07-20 · Rf 6.8% · Healthcare P/E 22.0 (n=2)
Technical timing lens
Trend score and candlestick chart
63BullishMACD − · sector +4.0pp vs Nifty 500 (3M)
Stock trend: 50
Sector RS: 83
Sector 3M: +0.0% vs Nifty 500 -4.1%
Healthcare FPI tailwindBuilding
Latest FPI flow is positive, but a second consecutive positive fortnight is still required. View sector evidence
Technical chart
MOMSBELIEFD candles · FIT view+10.1%Latest close ₹251.36 on 2026-11-04
Daily history is available from 2026-09-08; the requested 1Y window is partially covered.
Bar
+0.3%
RSI
52
MACD hist
-1.09
52W pos
44%
2026-11-04O ₹250.50H ₹255.45L ₹248.00C ₹251.36Vol 1.9L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MOMSBELIEFNifty Healthcare IndexNifty 500
- MOMSBELIEF
- +10.1%
- Nifty 500
- -1.5%
- Nifty Healthcare Index
- +0.5%
- Vs Nifty 500
- +11.5 pp
Chart stats
4 Nov 2026- From 52W high
- -20.2%
- 52W range position
- 44%
- ATR (14)
- 8.3%
- Volume vs 20D
- 0.15x
- Avg traded value
- ₹33.8 Cr
- 20D price channel
- ₹201.1 - ₹315
₹315
₹201.1 - ₹315
₹21
Latest completed session
20-session average
97.8% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management trust is not scored yet, price trend is neutral, and result consistency is still building.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · OVERVALUED20
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish63
Price trend and sector-relative-strength timing.
Valuation
Legacy model-969.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
pending—
Management reliability not computed yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 28 Sept 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹25.3 Cr | NDF | +1.2% |
| EBITDA | ₹5 Cr | +968.1% | +5.0% |
| Operating margin | 19.8% | +1544 bps | +72 bps |
| PAT | ₹2.8 Cr | NDF | +16.7% |
| PAT margin | 11.0% | +1606 bps | +146 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 61.80
- P/B
- —
- EV/EBITDA
- 31.27
- Market Cap
- 512.00Cr
Profitability
- ROE
- 16.10%
- ROCE
- —
- ROA
- 9.75%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- —
- EPS 5Y
- —
- Revenue 3Y
- —
- EPS 3Y
- —
Balance Sheet
- Debt/Equity
- 0.30
- Interest Coverage
- 8.03×
- Altman Z
- 9.04
- Book Value
- —
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -1.94 Cr
- EPS TTM
- 3.18
Shareholding
- Promoter Hold
- 68.77%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 39%
Financial History
Updated 4/11/2026
Revenue
₹ CrLatest: 25.3+1.2% vs prev
Net Profit
₹ CrLatest: 2.8+16.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 52.
- RSI(14) at 52 — sideways, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 20% off 52W high · 25% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
-
RS percentile
Insufficient history
1M return
+8.2%
3M return
-
6M return
-
1Y return
-
RS 1D
-
RS 20D
-
Sector rank
-
Industry rank
-
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
unavailable
200-DMA
unavailable
Sector
unranked
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
38 observations
03 Nov 2026Value 111.24-5.00%
RS vs Nifty 500111
Valuation & peers
U-Score 20 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 20 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth2/25
Quality7/20
Balance Sheet10/15
Cash Flow0/10
Piotroski
4/9 (+1)
Penalties
0
Raw sum
20
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
20/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 10/15 to the score.
- Quality contributes 7/20 to the score.
- Growth contributes 2/25 to the score.
Main drags
- Fair-value margin of safety is negative at -969.5%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
61.8
PB
—
EV/EBITDA
31.3
ROE
16.1%
ROCE
—
FCF Yield
—
Debt/Equity
0.3
MoS
-969.5%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 05 Nov 2026
v4.3-runtime-valuation
Final score
20
Previous: 21 (-1)
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-969.5%
Previous: -969.5%
Score history
12 stored score snapshots. Latest stored move: +0 points.
05 Nov 2026
v4.3-runtime-valuation
20
20
20
20
20
20
20
20
21
21
21
21
Factor attribution
Quality
7-1
was 8
Modelled fair value
Graham Number
—
Growth-justified P/E
7.4
Growth-justified Value
₹23.5
-969.5% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Healthcare — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
VALIANTLAB
Small
Valiant Laboratories Limited
Healthcare Services
match 112
13
42.2
-2.5%
-4169%
OVERVALUED
QMSMEDI
SME
QMS Medical Allied Services Ltd.
Healthcare Services
match 112
32
32.6
10.4%
+31%
WATCHLIST
CHANDAN
SME
Chandan Healthcare Ltd.
Healthcare Services
match 112
58
21.9
19.8%
+50%
FAIR VALUE
LYKALABS
Small
Lyka Labs Limited
Healthcare Services
match 111
17
—
-10.2%
—
OVERVALUED
ZIMLAB
Small
Zim Laboratories Limited
Healthcare Services
match 111
17
369.1
1.6%
-12572%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Rays of Belief Limited operates in Hospital, within the Healthcare sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
Trust profile pending
Trust asks a simple question: can investors rely on management behaviour and financial delivery? Trust Lite uses promoter alignment, cash conversion, leverage, and result consistency. Full transcript-based claim matching appears after enough documents are ingested.
Continue researching Rays of Belief Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Acquisition 19 Sep - 100% acquisition of City Pro Group Inc. for USD 2 million; became step-down subsidiary on September 18, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 21 Sep - Rays of Belief acquired 100% of City Pro Group via subsidiary, effective September 18, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 1 Oct - Q1 FY27 results: revenue ₹253.14 Mn, EBITDA ₹50.77 Mn, net profit ₹27.87 Mn.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Sep - Please find enclsoed Newspaper Publication for Un-audited Financial Results for the Quarter ended June 30, 2026
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.